• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Connecticut State Medical Society and Genomas Co-Sponsor Forum on DNA-Guided Medicine and the Path to Personalized Health Care

Posted on: Wednesday, 24 September 2008, 09:00 CDT

WATERBURY, Conn., Sept. 24 /PRNewswire/ -- The Connecticut State Medical Society is joining with Genomas(R), a biomedical company advancing DNA-guided medicine and personalized healthcare, to co-sponsor a symposium -- DNA-Guided Medicine and the Path to Personalized Health Care -- being held today at the Society's annual meeting. Hartford Hospital is providing continuing medical education credits for physicians attending the meeting.

Lawrence J. Lesko, Ph.D., Director of the Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, will discuss FDA Initiatives in Personalized Medicine: Advancing Individualized Drug Therapy.

Dr Lesko commented: "The U.S. Department of Health and Human Services and the FDA have prioritized personalized medicine as one of their mission goals for public health. I am glad to participate in this event with the Connecticut Medical Society, Hartford Hospital and Genomas to bring these initiatives to physicians who are in an important position to implement them in their clinical practice. Connecticut is poised to become one of the national leaders in adoption of personalized medicine, and I am thrilled to join ranks with these local efforts as exemplary to improving the healthcare system as a whole."

Gualberto Ruano, M.D., Ph.D., President and CEO of Genomas, will speak about Progress Towards DNA-Guided Medicine in Clinical Practice: Case Studies in Cardiology and Psychiatry. Examples in these two therapeutic areas include statins and atypical antipsychotics.

Dr. Ruano commented: "We are privileged to partner with the Connecticut State Medical Society to convene the physicians in our state for this forum. The presence of the FDA is an indication of the national impact of the programs in DNA-Guided Medicine that Genomas has spearheaded in Connecticut with Hartford Hospital and the Hospital of Central Connecticut. Together, we are bringing personalized healthcare to our patients today, and setting the pathway to utilization of DNA-Guided Medicine as the standard of care in cardiovascular and psychiatric clinical practice."

ABOUT GENOMAS

Genomas Inc. is a biomedical company advancing DNA-guided medicine and personalized healthcare. The company develops revolutionary PhyzioType(TM) Systems for DNA-guided diagnosis and prevention of metabolic disorders induced by drugs in cardiovascular and psychiatric medicine. PhyzioType Systems are designed to provide physicians with the unprecedented capability to select for each patient the safest drug treatment to enhance compliance. Genomas is located in Hartford, CT on the campus of Hartford Hospital. For more information, please visit http://www.genomas.net/

ABOUT PHYZIOTYPE CLINICAL MANAGEMENT SYSTEMS

PhyzioType Systems are composed of an ensemble of inherited DNA polymorphisms genotyped by arrays and interpreted by a biomathematical algorithm in order to convey to physicians predicted comparisons of side effect risk among drugs for the individual patient. To date, Genomas has secured $3.1 million from NIH Small Business Innovation Research (SBIR) for PhyzioType System product development.

Genomas Inc.

CONTACT: Gualberto Ruano, MD, PhD, President and CEO of Genomas Inc.,+1-860-545-4574

Web site: http://www.genomas.net/

Source: PRNewswire

More News in this Category